论文部分内容阅读
恶性肿瘤是当今世界范围内人类最重要的死亡原因之一。目前治疗肿瘤的三种主要方法是外科手术、放射治疗和化学治疗。近年来,随着肿瘤相关分子生物学及病理生理学研究的迅猛发展,肿瘤的相关发病机制也得到进一步阐明,肿瘤的特异性治疗—靶向治疗由此应运而生。白细胞介素-13受体(主要是interleukin-13 receptorα2)在肿瘤细胞上高表达,而在正常组织细胞中不表达或极低表达,此特性使得IL-13Rα2介导的融合蛋白在肿瘤靶向治疗方面成为当前研究的热点与重点之一,并为融合蛋白在临床中的应用提供了新的理论依据。该文将主要对IL-13及其受体特点,IL-13受体在肿瘤中表达的相关研究及其受体介导的融合蛋白在肿瘤治疗中的研究进展等作一综述。
Malignancy is one of the most important causes of human death in the world today. Currently the three main methods of treating tumors are surgery, radiotherapy and chemotherapy. In recent years, with the rapid development of tumor-related molecular biology and pathophysiology, the related pathogenesis of tumors has been further clarified. Tumor-specific therapy-targeted therapy has emerged as a result. Interleukin-13 receptor (mainly interleukin-13 receptorα2) is highly expressed on tumor cells, but not expressed in normal tissue cells or very low expression, this feature makes IL-13Rα2-mediated fusion protein in tumor targeting Treatment has become one of the hot spots and focuses of current research, and provided a new theoretical basis for the application of fusion protein in clinic. This article will mainly review the characteristics of IL-13 and its receptor, the expression of IL-13 receptor in tumor and the research progress of its receptor-mediated fusion protein in tumor therapy.